Posted by Michael Wonder on 16 Dec 2021
EMA recommends approval for use of Kineret in adults with COVID-19
16 December 2021 - EMA’s CHMP has recommended extending the indication of Kineret (anakinra) to include treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen (low or high flow oxygen) and who are at risk of developing severe respiratory failure, as determined by blood levels of a protein called suPAR (soluble urokinase plasminogen activator receptor) of at least 6 ng/mL.
In reaching its conclusion, the CHMP evaluated data from a study involving 606 hospitalised adults with moderate or severe COVID-19 pneumonia and who had suPAR levels of at least 6 ng/mL.
